Beam Therapeutics Inc (BEAM)

NASD · Healthcare · Biotechnology · USA

Beam Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Beam Therapeutics is a biotechnology company developing precision genetic medicines based on its proprietary base editing technology, which modifies individual DNA bases without creating double-stranded breaks. The company advances a portfolio of investigational therapies targeting hematology and genetic diseases through ex vivo and in vivo delivery approaches, supported by internal manufacturing capabilities at its facility in North Carolina.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Beam Therapeutics Inc stock.

Our verdict on BEAM

Overvalued: intrinsic value $11.10 per share, market price $20.65, margin of safety -86.1% (as of 2026-11-17).

A 2.4x revenue multiple, discounted for its losses, values the shares at $11.10; the price of $20.65 is 86% above that value.

ETFs with the most weight in BEAM

17 more funds hold it; the full list is part of the paid plan.

More on BEAM

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than BEAM in Biotechnology

49 more in this industry show a wider margin of safety.

Is BEAM undervalued or overvalued?

BEAM is overvalued (as of the 2026-11-17 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $11.10; the price of $20.65 is 86% above that value.

What is the intrinsic value of BEAM?

$11.10 per share (as of the 2026-11-17 close), against a market price of $20.65. That is a margin of safety of -86.1%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.